LWANC
ABBV icon

Laurel Wealth Advisors (North Carolina)’s AbbVie ABBV Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.63M Sell
30,317
-185
-0.6% -$39.8K 0.74% 29
2026
Q1 		$6.15M Buy
30,502
+105
+0.3% +$23.3K 0.61% 33
2025
Q4 		$6.95M Sell
30,397
-448
-1% -$102K 0.92% 29
2025
Q3 		$7.14M Buy
30,845
+104
+0.3% +$21.2K 1% 25
2025
Q2 		$5.71M Sell
30,741
-128
-0.4% -$23.8K 0.85% 33
2025
Q1 		$6.47M Sell
30,869
-524
-2% -$102K 1.01% 26
2024
Q4 		$5.58M Sell
31,393
-344
-1% -$63.2K 0.87% 30
2024
Q3 		$6.27M Sell
31,737
-450
-1% -$84K 1% 26
2024
Q2 		$5.52M Sell
32,187
-959
-3% -$159K 0.96% 26
2024
Q1 		$6.04M Sell
33,146
-134
-0.4% -$23.1K 1.03% 26
2023
Q4 		$5.16M Sell
33,280
-64
-0.2% -$9.33K 0.98% 29
2023
Q3 		$4.97M Sell
33,344
-2,104
-6% -$309K 1.05% 28
2023
Q2 		$4.78M Sell
35,448
-1,185
-3% -$174K 0.96% 30
2023
Q1 		$5.84M Buy
36,633
+653
+2% +$99.8K 1.23% 23
2022
Q4 		$5.81M Buy
35,980
+2,788
+8% +$427K 1.32% 21
2022
Q3 		$4.46M Buy
33,192
+2,444
+8% +$351K 1.11% 25
2022
Q2 		$4.71M Buy
30,748
+765
+3% +$117K 1.14% 27
2022
Q1 		$4.86M Sell
29,983
-366
-1% -$53.2K 1.02% 27
2021
Q4 		$4.11M Buy
30,349
+1,245
+4% +$147K 0.84% 35
2021
Q3 		$3.14M Sell
29,104
-1,318
-4% -$151K 0.69% 47
2021
Q2 		$3.43M Buy
30,422
+2,266
+8% +$255K 0.74% 41
2021
Q1 		$3.05M Buy
28,156
+2,670
+10% +$286K 0.74% 45
2020
Q4 		$2.73M Buy
25,486
+3,545
+16% +$341K 0.71% 45
2020
Q3 		$1.92M Buy
21,941
+4,312
+24% +$406K 0.57% 53
2020
Q2 		$1.73M Buy
17,629
+6,834
+63% +$602K 0.57% 56
2020
Q1 		$822K Buy
10,795
+1,175
+12% +$100K 0.31% 73
2019
Q4 		$852K Sell
9,620
-195
-2% -$16.2K 0.27% 74
2019
Q3 		$743K Sell
9,815
-660
-6% -$45.2K 0.25% 79
2019
Q2 		$762K Sell
10,475
-62
-0.6% -$4.87K 0.27% 77
2019
Q1 		$849K Sell
10,537
-360
-3% -$29.5K 0.31% 72
2018
Q4 		$1M Buy
+10,897
New +$958K 0.4% 66

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s ABBV Position: Q2 2026 in Review

Laurel Wealth Advisors (North Carolina) reduced its AbbVie (ABBV) stake by 0.61% in Q2 2026, selling an estimated $39.8K and leaving 30,317 shares worth $7.63M. The position accounts for 0.74% of the portfolio, ranked #29.

Laurel Wealth Advisors (North Carolina) first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. 838 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Laurel Wealth Advisors (North Carolina) held 30,317 shares of AbbVie worth $7.63M as of Q2 2026.
  • Laurel Wealth Advisors (North Carolina) sold 185 AbbVie shares in Q2 2026, an estimated $39.8K.
  • AbbVie made up 0.74% of Laurel Wealth Advisors (North Carolina)'s portfolio in Q2 2026, its #29 holding.
  • Laurel Wealth Advisors (North Carolina) first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
  • 838 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q2 2026, filed 17 Jul 2026.